Skip to main content
Erschienen in:

01.06.2020 | Research Article

Correlation between the contrast-enhanced ultrasound image features and axillary lymph node metastasis of primary breast cancer and its diagnostic value

verfasst von: H. Xu, G. L. Xu, X. D. Li, Q. H. Su, C. Z. Dong

Erschienen in: Clinical and Translational Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To analyze the correlation between contrast-enhanced ultrasound image features and axillary lymph node metastasis of primary breast cancer and its diagnostic value.

Methods

In this study, 64 patients with axillary lymph node metastasis of primary breast cancer diagnosed and treated in our hospital from February 2011 to March 2013 were collected as an observation group, and 54 patients without axillary lymph node metastasis were collected as a control group. All patients underwent a contrast-enhanced ultrasound examination, and the correlation between the contrast-enhanced ultrasound image features and axillary lymph node metastasis and its diagnostic value were analyzed. They were divided into two groups according to their survival conditions: the group with good efficacy and group with poor efficacy, and the prognostic factors of breast cancer in the two groups were analyzed.

Results

There were statistical differences in the peripheral acoustic halo, blood flow classification, ratio of length to diameter (L/D), maximum cortical thickness, and enhancement mode of lymph nodes between the two groups (p < 0.05). The area under ROC curve for diagnosis of axillary lymph node metastasis by contrast-enhanced ultrasound was 0.854, sensitivity was 83.33%, and specificity was 87.5%; L/D and enhancement mode were independent prognostic factors for breast cancer.

Conclusions

Contrast-enhanced ultrasound image features have diagnostic and prognostic value for axillary lymph node metastasis of breast cancer.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef
2.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRef
3.
Zurück zum Zitat Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRef Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRef
4.
Zurück zum Zitat Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.CrossRef Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.CrossRef
5.
Zurück zum Zitat Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF, EBCTCG. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–46.CrossRef Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF, EBCTCG. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–46.CrossRef
6.
Zurück zum Zitat Berg WA, Bandos AI, Mendelson EB, Lehrer D, Jong RA, Pisano ED. Ultrasound as the primary screening test for breast cancer: analysis from ACRIN 6666. J Natl Cancer Inst. 2015; 108 [pii: djv367] Berg WA, Bandos AI, Mendelson EB, Lehrer D, Jong RA, Pisano ED. Ultrasound as the primary screening test for breast cancer: analysis from ACRIN 6666. J Natl Cancer Inst. 2015; 108 [pii: djv367]
7.
Zurück zum Zitat Gié O, Matthey-Gié ML, Marques-Vidal PM, Demartines N, Matter M. Impact of the ultrasonic scalpel on the amount of drained lymph after axillary or inguinal lymphadenectomy. BMC Surg. 2017;17:27.CrossRef Gié O, Matthey-Gié ML, Marques-Vidal PM, Demartines N, Matter M. Impact of the ultrasonic scalpel on the amount of drained lymph after axillary or inguinal lymphadenectomy. BMC Surg. 2017;17:27.CrossRef
8.
Zurück zum Zitat Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of clinical oncology: American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.CrossRef Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of clinical oncology: American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.CrossRef
9.
Zurück zum Zitat Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35:561–4.CrossRef Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35:561–4.CrossRef
10.
Zurück zum Zitat Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta-analysis. Cancer. 2006;106:4–16.CrossRef Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta-analysis. Cancer. 2006;106:4–16.CrossRef
11.
Zurück zum Zitat Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, Port E, Sacchini V, Sclafani L, VanZee K, Wagman R, Borgen PI, Cody HS 3rd. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–71.CrossRef Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, Port E, Sacchini V, Sclafani L, VanZee K, Wagman R, Borgen PI, Cody HS 3rd. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–71.CrossRef
12.
Zurück zum Zitat Matsuzawa F, Einama T, Abe H, Suzuki T, Hamaguchi J, Kaga T, Sato M, Oomura M, Takata Y, Fujibe A, Takeda C, Tamura E, Taketomi A, Kyuno K. Accurate diagnosis of axillary lymph node metastasis using contrast-enhanced ultrasonography with Sonazoid. Mol Clin Oncol. 2015;3:299–302.CrossRef Matsuzawa F, Einama T, Abe H, Suzuki T, Hamaguchi J, Kaga T, Sato M, Oomura M, Takata Y, Fujibe A, Takeda C, Tamura E, Taketomi A, Kyuno K. Accurate diagnosis of axillary lymph node metastasis using contrast-enhanced ultrasonography with Sonazoid. Mol Clin Oncol. 2015;3:299–302.CrossRef
13.
Zurück zum Zitat Li K, Su ZZ, Xu EJ, Ju JX, Meng XC, Zheng RQ. Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma. BMC Cancer. 2016;16:277.CrossRef Li K, Su ZZ, Xu EJ, Ju JX, Meng XC, Zheng RQ. Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma. BMC Cancer. 2016;16:277.CrossRef
14.
Zurück zum Zitat Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F. ESMO guidelines committee: primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–v30.CrossRef Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F. ESMO guidelines committee: primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–v30.CrossRef
15.
Zurück zum Zitat Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours. 4th ed. Lyon: IARC WHO classification of tumours IARC Press; 2012. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours. 4th ed. Lyon: IARC WHO classification of tumours IARC Press; 2012.
16.
Zurück zum Zitat Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72:333–8.CrossRef Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72:333–8.CrossRef
17.
Zurück zum Zitat Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Menopause Rev. 2015;14:196–202.CrossRef Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Menopause Rev. 2015;14:196–202.CrossRef
18.
Zurück zum Zitat Lynch BM, Neilson HK, Friedenreich CM. Physical activity and breast cancer prevention. Phys Activ Cancer. 2011;186:13–42.CrossRef Lynch BM, Neilson HK, Friedenreich CM. Physical activity and breast cancer prevention. Phys Activ Cancer. 2011;186:13–42.CrossRef
19.
Zurück zum Zitat Layeequr Rahman R, Crawford SL, Siwawa P. Management of axilla in breast cancer—the saga continues. Breast. 2015;24:343–53.CrossRef Layeequr Rahman R, Crawford SL, Siwawa P. Management of axilla in breast cancer—the saga continues. Breast. 2015;24:343–53.CrossRef
20.
Zurück zum Zitat Zhang YX, Wang XM, Kang S, Li X, Geng J. Contrast-enhanced ultrasonography in qualitative diagnosis of sentinel lymph node metastasis in breast cancer: A meta-analysis. J Cancer Res Ther. 2015;11:697.CrossRef Zhang YX, Wang XM, Kang S, Li X, Geng J. Contrast-enhanced ultrasonography in qualitative diagnosis of sentinel lymph node metastasis in breast cancer: A meta-analysis. J Cancer Res Ther. 2015;11:697.CrossRef
21.
Zurück zum Zitat Choi HY, Park M, Seo M, Song E, Shin SY, Sohn YM. Preoperative axillary lymph node evaluation in breast cancer: current issues and literature review. Ultrasound Q. 2017;33:6–14.CrossRef Choi HY, Park M, Seo M, Song E, Shin SY, Sohn YM. Preoperative axillary lymph node evaluation in breast cancer: current issues and literature review. Ultrasound Q. 2017;33:6–14.CrossRef
22.
Zurück zum Zitat Dellaportas D, et al. Contrast-enhanced color Doppler ultrasonography for preoperative evaluation of sentinel lymph node in breast cancer patients. Breast Care (Basel). 2015;10(5):331–5.CrossRef Dellaportas D, et al. Contrast-enhanced color Doppler ultrasonography for preoperative evaluation of sentinel lymph node in breast cancer patients. Breast Care (Basel). 2015;10(5):331–5.CrossRef
23.
Zurück zum Zitat Cheng W, et al. Percutaneous contrast-enhanced ultrasonography to observe the sentinel lymph node metastasis of tumor-bearing rabbit breast cancer. Chin J Med Imag Technol. 2014;30(8):1161–4. Cheng W, et al. Percutaneous contrast-enhanced ultrasonography to observe the sentinel lymph node metastasis of tumor-bearing rabbit breast cancer. Chin J Med Imag Technol. 2014;30(8):1161–4.
24.
Zurück zum Zitat Liu J, et al. Percutaneous contrast-enhanced ultrasound for localization and diagnosis of sentinel lymph node in early breast cancer. Sci Rep. 2019;9(1):1–6.CrossRef Liu J, et al. Percutaneous contrast-enhanced ultrasound for localization and diagnosis of sentinel lymph node in early breast cancer. Sci Rep. 2019;9(1):1–6.CrossRef
25.
Zurück zum Zitat Sharma N, Cox K. Axillary nodal staging with contrast-enhanced ultrasound. Curr Breast Cancer Rep. 2017;9:259–63.CrossRef Sharma N, Cox K. Axillary nodal staging with contrast-enhanced ultrasound. Curr Breast Cancer Rep. 2017;9:259–63.CrossRef
26.
Zurück zum Zitat Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol. 2016;59:651–72.CrossRef Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol. 2016;59:651–72.CrossRef
27.
Zurück zum Zitat Zhao YX, Liu S, Hu YB, Ge YY, Lv DM. Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study. Oncol Target Ther. 2017;10:1123.CrossRef Zhao YX, Liu S, Hu YB, Ge YY, Lv DM. Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study. Oncol Target Ther. 2017;10:1123.CrossRef
28.
Zurück zum Zitat de Azambuja E, Cardoso F, de CastroJr G, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504–13.CrossRef de Azambuja E, Cardoso F, de CastroJr G, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504–13.CrossRef
29.
Zurück zum Zitat Zhao XY, et al. Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study. Oncol Target Ther. 2017;10:1123.CrossRef Zhao XY, et al. Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study. Oncol Target Ther. 2017;10:1123.CrossRef
30.
Zurück zum Zitat Vraka I, Panourgias E, Sifakis E, Koureas A, Galanis P, Dellaportas D, Gouliamos A, Antoniou A. Correlation between contrast-enhanced ultrasound characteristics (qualitative and quantitative) and pathological prognostic factors in breast cancer. Vivo. 2018;32:945–54.CrossRef Vraka I, Panourgias E, Sifakis E, Koureas A, Galanis P, Dellaportas D, Gouliamos A, Antoniou A. Correlation between contrast-enhanced ultrasound characteristics (qualitative and quantitative) and pathological prognostic factors in breast cancer. Vivo. 2018;32:945–54.CrossRef
31.
Zurück zum Zitat Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2019;34:927.CrossRef Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2019;34:927.CrossRef
Metadaten
Titel
Correlation between the contrast-enhanced ultrasound image features and axillary lymph node metastasis of primary breast cancer and its diagnostic value
verfasst von
H. Xu
G. L. Xu
X. D. Li
Q. H. Su
C. Z. Dong
Publikationsdatum
01.06.2020
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 1/2021
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02407-6

Neu im Fachgebiet Onkologie

Kopf-Hals-Tumoren: Die Immuntherapie ist kein Selbstläufer

Ergebnisse einer weiteren Studie legen nahe: Mit einer adjuvanten Immuncheckpointhemmung ist lokal fortgeschrittenen Plattenepithelkarzinomen des Kopf-Hals-Bereichs nur schwer beizukommen. Einige Fachleute geben die Hoffnung jedoch nicht auf und diskutieren mögliche Gründe für die negativen Ergebnisse.

Dänische Zwillingsstudie deutet auf erhöhtes Krebsrisiko bei Tätowierten hin

Haben Tattoo-Träger und -Trägerinnen ein erhöhtes Risiko, an Hautkrebs oder einem Lymphom zu erkranken? Die Ergebnisse einer Zwillingsstudie aus Dänemark scheinen dafür zu sprechen. Die Forschungsgruppe rät vorerst zur Zurückhaltung beim Tätowieren.

Weniger PSA-Screening, mehr fortgeschrittene Tumoren

Eine Empfehlung gegen das Prostatakrebs-Screening, die mehrere Jahre in den Leitlinien des Royal Australasian College of General Practitioners gegeben wurde, hat sich nicht nur auf die Rate von PSA-Tests negativ ausgewirkt.

Schützt kutane Autoimmunität vor Hauttumoren?

Schwedische Registerdaten deuten auf ein geringeres Risiko für bestimmte Hauttumoren bei Personen mit Vitiligo oder autoimmuner Alopezie. Wie es dazu kommt, ist dagegen unklar.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.